このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

がん患者の肥満指数 (BMI) と生活の質 (QoL) (BMI-QoL)

2026年9月19日 更新者:Vincenzo Formica、University of Rome Tor Vergata

BMI is a simple and widely recorded variable that may capture obesity or cachexia in cancer patients. How BMI is associated to health-related quality of life (HR-QoL) in such patients is poorly investigated.

High BMI may be associated to obesity, an increased burden of comorbidity, reduced physical activity and, in some settings, to more aggressive oncological disease. On the other hand, low BMI may reflect enhanced weight loss, cachectic syndrome, higher tumor burden and adverse prognostic features which all deteriorate quality of life. The aim of the present study is to evaluate the association of BMI and HR-QoL as measured by the EORTC-QLQ-C30 or the EQ-5D-5L questionnaire in several cancer settings (such as localized vs metastatic or distinct primary tumors).

調査の概要

状態

募集

詳細な説明

Health-related quality of life (HRQoL) might have a varied association with body weight in patients with solid cancer[1].

On one hand, low body weight may reflect cancer-related anorexia and weight loss and cachectic syndrome, which are associated with impaired performance status, deteriorated general conditions, and advanced cancer[2]. In such patients, the probability of recording a low Body Mass Index (BMI) and, concomitantly, an inferior health-related quality of life (HRQoL, as a patient reported outcome, PRO) is high.

On the other hand, some of the hormonal mediators found at increased concentration in obese patients, such as insulin-like growth factor (IGF), have been demonstrated to be involved in biological pathways that favor improved HRQoL[3].

An additional apparent contradiction is that obesity and high BMI may represent in some cancer settings an adverse feature. In particular, obesity is associated with an increased risk of developing certain tumor types and, in some cancer patients with radically resected primary tumors, of cancer relapse[4]. Moreover high BMI is often associated with an increased burden of comorbidity (e.g. cardiovascular and metabolic diseases)[5] and reduced physical activity. All these factors may reduce HRQoL.

Studies investigating specific associations between BMI and HRQoL in specific cancer settings are therefore warranted.

The present prospective observational cohort study aims to investigate the relationship between BMI and PRO-HRQoL as measured by the EORTC-QLQ-C30 or the EQ-5D-5L questionnaire [6] in different primary tumors (breast, lung, colorectal and others) and in different cancer stages (localized vs metastatic). Patients will also be stratified according to the presence of cardiovascular and metabolic comorbidities, the Karnofsky Performance status, and the oncological treatment received (systemic treatment vs radically resected patients on follow-up). If available, retrospective data will be used to train possible predictive models.

STUDY PROCEDURES Study participation will be offered to all consecutive patients with a histologically confirmed diagnosis of solid tumor referred to the Medical Oncology Units of the S.I.C.O.G. cooperative group (http://www.sicog.it/). Upon acceptance, patients will sign an informed consent forms and be asked to fill out the EORTC QLQ C30 or EQ-5D-5L questionnaire.

All common anthropometric, demographic, clinical, and biochemical variables will be recorded at the time of first referral (within three months).

Re-assessable variables, including re-administration of the EORTC QLQ-C30/EQ-5D-5L questionnaire, will be recorded every 4-6 months thereafter. All data will be stored in a prospectively maintained database.

Among recorded data will be: age, sex, weight, height, occupation, marital status, primary tumor site, tumor stage, possible metastatic sites, past and current type of oncological treatment, concomitant medications, Karnofsky Performance Status, vital signs, and routine and clinically relevant blood tests.

Patients will be oncologically managed according to standard practice. If indicated, patients will also be asked to provide consent for peripheral blood sampling for immune response evaluation. Association between BMI and PROs will be assessed using regression analyses across the different clinical settings identified.

STATISTICAL CONSIDERATIONS The design of the study hypothesizes that in metastatic patients an improved HR-QoL is associated with high BMI (non-cachectic patients) An 'exact single-stage design' will be followed [7]. According to historical data (endometrial cancer), 50% of patients with BMI < 30 have a high global health status score (GHS) of the EORTC QLQ C30 (i.e. a GHS score ≥ 80%, which would correspond to a EQ-5D-5L index ≥ 0.85) [8].

The hypothesis to be tested will be H0, P < P0 vs H1, P > P1, where P is the percentage of patients with GHS ≥ 80%. A one-tail alpha error of 0.05 and false-negative (beta) rate of 0.2 will be considered. P0 will be set at 50% and P1 at 65%, looking for a 15% increase in the percentage of high GHS scores among patients with BMI >30. The H0 hypothesis will be rejected and H1 accepted with a statistical power of 80% if at least 42 patients out of 69 with BMI > 30 report a GHS score ≥ 80.

Since BMI > 30 is observed in about 10% of all metastatic patients, a total of 690 metastatic patients will be required. Since metastatic patients represent about half of all cancer patients referred to Medical Oncology Units, a final sample size of 1380 cancer patients (all stages) will be set as the target number. Secondary analyses will evaluate the extent to which clinical and biochemical characteristics documented during the observation period moderate the association between BMI and HRQoL. Additionally, these analyses will quantify the relative contributions of both BMI and HRQoL to anticancer treatment outcomes and overall survival.

研究の種類

観察的

入学 (推定)

1380

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

      • Rome、イタリア、00133
        • 募集
        • Tor Vergata University Hospital
        • コンタクト:
          • Cristiano Serci
          • 電話番号:+390620908190

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

All consecutive patients with a histologically confirmed diagnosis of solid tumor referred to any of the Medical Oncology Units of the S.I.C.O.G. cooperative group (http://www.sicog.it/).

説明

Inclusion Criteria:

  1. Histologically confirmed diagnosis of solid tumor
  2. Age >18 years
  3. Signed informed consent
  4. Life expectancy > 12 weeks

Exclusion Criteria:

  1. Inability to fill out the questionnaires.
  2. Absence of a certain diagnosis of solid tumor (e.g. subjects on screening programs)
  3. Diagnosis of second malignancies that might bias results interpretation

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
patients with solid tumor

All consecutive patients with a histologically confirmed diagnosis of solid tumor referred to any of the Medical Oncology Units of the S.I.C.O.G. cooperative group (http://www.sicog.it/).

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
relationship between BMI and health-related quality-of-life scores according to tumor stage
時間枠:Recruitment period of 36 months + follow-up period of 24 months since enrollment of last patient

To assess the relationship between BMI and health-related quality-of-life scores in localized vs metastatic cancer patients

Recruitment period of 36 months + follow-up period of 24 months since enrollment of last patient

二次結果の測定

結果測定
メジャーの説明
時間枠
relationship between BMI and health-related quality-of-life scores according to different clinical settings other than stage
時間枠:Recruitment period of 36 months + follow-up period of 24 months since enrollment of last patient

- To assess the relationship between BMI and health-related quality-of-life scores according to:

  • primary tumor
  • presence vs absence of cardiovascular and/or metabolic comorbidities
  • Performance status
  • Ongoing chemotherapy treatment vs observation in disease-free patients (follow-up)
  • Other clinical and biochemical variables routinely assessed as common practice
Recruitment period of 36 months + follow-up period of 24 months since enrollment of last patient

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • スタディチェア:Mario Roselli、Tor Vergata University Hospital

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2019年1月15日

一次修了 (推定)

2029年1月15日

研究の完了 (推定)

2034年1月15日

試験登録日

最初に提出

2019年3月11日

QC基準を満たした最初の提出物

2019年3月11日

最初の投稿 (実際)

2019年3月13日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月23日

QC基準を満たした最後の更新が送信されました

2026年9月19日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する